Latest total revenue for ECTE: $0, below the sector sector average of $1.1B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2016
Trailing 12 months ending Sep 2016
As of the most recent data (September 2016), ECTE shows a total revenue of $0. In the prior-year period, the figure was $0. That is below the sector sector average of $1.1B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ECTE's total revenue is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Echo Therapeutics is outperforming or lagging.
The its sector sector average total revenue is about $1.1B. Echo Therapeutics is at $0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how ECTE stacks up against individual peers as well.
Tracking ECTE's total revenue over time shows whether Echo Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Echo Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $0) with ownership activity and broader fundamentals.